The market for cancer treatments is one of the largest and fastest growing areas in the pharma industry. Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in the genomics, transcriptomics and proteomics sciences. Successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. More recently, biotech companies have been driving innovation in oncology more than ever before. Partnering with biotech companies is an important but expensive source of innovation for many pharma companies, with approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.

‘The Cancer Market Outlook to 2013’ is a new report published by Business Insights that provides comprehensive coverage of the major markets in the global cancer area, incorporating a detailed epidemiological analysis of the nine major indications and key factors impacting their prevalence. Current leading brands of treatment within each cancer indication are analysed and eight of the market’s leading players are profiled. With coverage of over 90% of the total market for cancer products, this report profiles the factors and underlying trends that are driving market transformation and identifies the most promising areas of potential growth. Forecasts for currently marketed and key pipeline products over the 2007-13 period are also provided.

Discover the key market trends and growth drivers of the cancer market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this report...

Assess leading brands of treatment for each indication, identify potential growth opportunities and compare the outlooks of leading companies within the cancer market with this new report...

Some key findings from this report...

• Antineoplastic mAbs accrued sales of $11.3bn in 2007, amassing a market share of 34.1%. The most prominent contributors to market share in this class were MabThera (32.8%), Herceptin (28.8%), Avastin (25.2%) and Erbitux (10.2%). The total antineoplastics market is forecast to be valued at $43.0bn in 2013.
• Amgen’s blockbuster brands Neulasta (pegfilgrastim) and Neupogen (filgrastim) dominated the immunostimulant market in 2007, with sales of $3.5bn and $1.4bn respectively. Forecast sales for the immunostimulants market are estimated to reach $17.6bn in 2013.
• Roche is the leader in the global market for cancer treatments, with a market share of 34.9% (equivalent to $13bn sales) in 2007. Roche has recently bolstered its position through portfolio expansion, with the purchase of majority stakes in both Genentech and Chugai.
• A definitive merger between Eli Lilly and ImClone will increase Eli Lilly’s flow of high-quality, innovative therapies. This will enable the company to offer physicians/patients a complementary portfolio of leading agents/targeted therapies including Gemzar, Alimta & Erbitux.
• Pfizer has a robust R&D pipeline with eight molecules in phase II and thirteen molecules in phase I, the highest among all the top ten companies in global cancer market.

Top five reasons to order your copy today

• Assess patient potential, treatment trends and sales patterns of major cancer indications over the period 2007-13, with this report’s coverage of lung, breast, colorectal, ovarian cancer markets across Japan, France, Germany, Italy, Spain, the UK and the US.
• Measure the market performance and strategic positioning of major pharmaceutical corporations with this report’s evaluation of the franchises and market shares of Roche, Amgen, Sanofi-Aventis, Merck KgaA, Novartis, Pfizer, Schering-Plough and Eli Lilly.
• Discover the market dynamics of the cancer area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting product development.
• Compare the cancer pipeline compounds of leading companies with this report’s detailed analysis of clinically differentiated pipeline products by indication, in addition to sales forecasts for key R&D pipeline products in the global cancer market to 2013.
• Understand which indications are likely to generate franchise growth and examine major classes of cancer treatments including antineoplastics, immunostimulants and cytotoxic hormone therapies.

Key issues examined in this report...

• Reimbursement for cryoablation treatments. The new 2008 CMS rates for prostate cryoablation (in outpatient hospitals), under APC code 674, were raised from $6,685 to $7,816, an increase of 16.9%. The cryoablation rates for ambulatory surgical centers, known as ASC code 55873, were raised from $1,339 to $6,219, an increase of 364%.
• Plant-based cancer vaccine. Researchers are developing a plantbased vaccine which can be created more quickly and at far less expense than the animal-based version. The antibodies produced may also trigger a stronger immune response than in mammalian cells.
• Novel inhibitor of human microRNA. The Wistar Institute team have identified a small molecule that blocks the pathway of miR-21, which is implicated in brain cancer, as well as lung, colon, breast, and ovarian cancer. With further development, the molecule has the potential to boost patient response to existing chemotherapies.
• NICE guidance on kidney cancer drugs. The availability of high cost cancer drugs is one of the most pressing issues for the NHS. Drug makers are developing proposals which may reduce future drug costs.

Your questions answered...

• Which indications will experience the greatest growth in the global cancer market over the period 2008-13?
• How have recent major product launches from companies such as Roche, Amgen, Pfizer and Merck KGaA performed?
• What is the forecast market potential of the most exciting compounds currently in development for cancer indications?
•  Which companies are best positioned for future success?
• What is the forecast market size and growth rate over the period 2007-2013 across the major cancer indications?
• How will generic competition influence the future of branded products and which defensive strategies provide the most effective protection?
• Which pipeline products offer the highest growth potential?
• What will be the competitive landscape of lung, breast, colorectal, ovarian, prostate, lymphoma and pancreatic cancer in 2013?